Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to -$12.2 million.

  • Contineum Therapeutics' Cash from Operations fell 9771.44% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.5 million, marking a year-over-year decrease of 5735.15%. This contributed to the annual value of -$32.8 million for FY2024, which is 26975.04% down from last year.
  • Contineum Therapeutics' Cash from Operations amounted to -$12.2 million in Q3 2025, which was down 9771.44% from -$15.7 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Cash from Operations high stood at $40.7 million for Q2 2023, and its period low was -$15.7 million during Q2 2025.
  • Over the past 3 years, Contineum Therapeutics' median Cash from Operations value was -$8.5 million (recorded in 2024), while the average stood at -$5.1 million.
  • Data for Contineum Therapeutics' Cash from Operations shows a peak YoY increase of 468.98% (in 2024) and a maximum YoY decrease of 12089.54% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Cash from Operations (Quarter) stood at -$10.7 million in 2023, then rose by 4.69% to -$10.2 million in 2024, then dropped by 19.55% to -$12.2 million in 2025.
  • Its Cash from Operations was -$12.2 million in Q3 2025, compared to -$15.7 million in Q2 2025 and -$14.4 million in Q1 2025.